News

Hemo Organic Limited on Saturday, October 3, 2026, approved alterations to its Memorandum of Association, including changes to its main objects to cover activities related to diamonds, real estate, and investments, and increased its authorized share capital from Rs 13.45 crore divided into 13.45 million equity shares to Rs 125 crore divided into 12.5 million equity shares. The company also appointed Pratibha Sharma as Company Secretary and Compliance Officer, effective October 3, 2026, while deferring a proposal for fundraising to a future board meeting.

Hemo Organic Limited informed the BSE Limited that the trading window for dealing in Equity Shares of the company by insiders, designated persons, and their immediate relatives will be closed from Thursday, October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half year ending September 30, 2026.

Hemo Organic Limited informed the BSE Limited that the meeting of the Board of Directors scheduled for Wednesday, September 23, 2026, has been cancelled due to unavoidable reasons, as previously intimated on September 19, 2026, under Regulation 29 of SEBI (LODR) Regulations, 2015.

Hemo Organic Limited will seek shareholder approval to raise funds in one or more tranches through the issue of equity shares and/or convertible securities, including convertible warrants, via methods such as preferential allotment, private placement, or public issue, according to a regulatory filing with the BSE Limited on September 19, 2026. The company’s trading window will be closed from the end of business hours on September 19, 2026, until 48 hours after the conclusion of the board meeting scheduled for September 23, 2026.

Hemo Organic Limited announced the appointment of Mr. Ayush Dharmendrabhai Jasani (DIN: 09842741) as an Additional Director and Chairperson of the company, effective September 9, 2026, subject to member approval.